TM Owner AstraZeneca
Tezspire 210mg/1.91ml Injection
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Tezspire 210 mg/1.91 mL contains tezepelumab-ekko, a human monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), an upstream signal that drives airway inflammation regardless of allergy or eosinophil status.
- It is approved as an add-on maintenance treatment for severe asthma in patients aged 12 years and older whose symptoms are not controlled by current inhaled therapies, without needing a specific blood eosinophil count or allergic trigger to qualify, and, more recently, as add-on maintenance treatment for chronic rhinosinusitis with nasal polyps that remains inadequately controlled.
- Tezspire is co-developed and co-marketed by Amgen and AstraZeneca; it is given by subcutaneous injection once every 4 weeks, either self-injected at home after training using a prefilled syringe or pen, or given by a healthcare provider, and is not for treating a sudden asthma attack.
Side Effects
- Tezspire has no boxed warning.
- In asthma trials the most common effects were sore throat (pharyngitis), joint pain and back pain; in the chronic rhinosinusitis trials, sinus and upper airway infections, nosebleeds, sore throat, flu-like illness and injection-site reactions were also reported.
- The main serious risk is hypersensitivity, including rare anaphylaxis, which can occur shortly after a dose.
- Seek urgent medical help for swelling of the face, lips, tongue or throat, sudden difficulty breathing, widespread rash, dizziness or fainting after an injection.
- Tezspire is not a rescue treatment - always keep your usual reliever inhaler with you for sudden symptoms.
Precautions & Warnings
- Tezspire must not be used to treat a sudden asthma attack or status asthmaticus, and is contraindicated only in known hypersensitivity to tezepelumab or its excipients.
- Do not stop or rapidly lower corticosteroids when starting Tezspire; any reduction should be gradual and supervised, since asthma control can worsen if steroids are withdrawn too quickly.
- Treat any existing parasitic (helminth) infection before starting, as Tezspire may reduce the immune response needed to clear it.
- Avoid live or live-attenuated vaccines while on treatment.
- Data in pregnancy and breastfeeding are limited, so discuss the balance of benefit and risk individually with your prescriber.
Avoid Interactions
- No formal drug-interaction studies have been carried out with Tezspire, and as a large monoclonal antibody it is not expected to interact through the liver enzyme pathways that affect most small-molecule medicines.
- Commonly used asthma treatments, including inhaled corticosteroids, long-acting bronchodilators, leukotriene modifiers and theophylline, showed no clinically meaningful interaction when used alongside it in studies.
- Avoid live or live-attenuated vaccines during treatment.
- Tell your healthcare provider about every other medicine you take, particularly any other biologic therapy for asthma or nasal polyps, before starting Tezspire, since combining biologics is not established.
References
Frequently Asked Questions
Tezspire (tezepelumab) is an add-on injection for severe asthma not controlled by inhalers alone, and for chronic rhinosinusitis with nasal polyps that remains inadequately controlled. It blocks TSLP, a signal that drives airway inflammation, and works regardless of your allergy status or eosinophil count.
Tezspire 210 mg is injected under the skin once every 4 weeks, using a prefilled syringe or pen, either by you at home after training or by a healthcare provider. It is a long-term maintenance treatment, not a rescue medicine for sudden symptoms.
The most common effects are sore throat, joint pain and back pain. Rarely, a serious allergic reaction (anaphylaxis) can occur soon after injection - seek urgent help for facial swelling, breathing difficulty or widespread rash. Tezspire carries no boxed warning.
Avoid live or live-attenuated vaccines while on Tezspire. Don't stop or rapidly reduce your corticosteroids when starting it - any tapering must be gradual and supervised. Treat any existing parasitic infection first. Always keep a reliever inhaler for sudden asthma symptoms.
Keep Tezspire refrigerated at 2C to 8C in its original carton, protected from light. If needed, it can be kept at room temperature (20C to 25C) for up to 30 days. Do not shake it, and let it warm up for about an hour before injecting.
Tezspire is approved for patients aged 12 and older with severe asthma or chronic rhinosinusitis with nasal polyps meeting the criteria; it is not approved for children under 12. Your prescriber will confirm whether your child's age and condition make them suitable for treatment.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
